Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scleritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.
Abstract: The present invention relates to novel JNK inhibitor molecules. The present invention furthermore relates to methods for raising antibodies against such JNK inhibitor molecules as well as to the respective antibodies and cells producing said antibodies.
Abstract: The present invention relates to novel transporter constructs of the generic formula (I) DlLLLxDm(LLLyDn)a and variants thereof. The present invention also refers to transporter cargo conjugate molecules, particularly of conjugates of the novel transporter constructs with a cargo moiety, e.g. proteins or peptides, nucleic acids, cytotoxic agents, organic molecules, etc. The present invention furthermore discloses (pharmaceutical) compositions comprising these conjugates and methods of treatment and uses involving such transporter constructs.
Abstract: The present invention relates to the use of specific transporter cargo conjugate molecules for the transport of a substance of interest (cargo molecule) into white blood cells. Said transporter cargo conjugate molecules may be used for the treatment, prophylaxis, attenuation and/or amelioration of a disease and/or disorder involving white blood cells. The present invention also relates to manufacture of said transporter cargo conjugate molecules, to a method of transporting a substance of interest (cargo) into a white blood cell and to a white blood cell comprising said transporter cargo conjugate molecules or fragments thereof.
Abstract: The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.
Abstract: This invention relates to a fusion protein comprising at least one first portion (I) comprising a trafficking sequence and at least one second portion (II) comprising a full-length or partial BH3-domain sequence of a BH3-only protein, said fusion protein comprising D-enantiomeric amino acids in retro-inverso order in its portion (I). Furthermore, the invention relates to pharmaceutical compositions containing said fusion protein as well as to the use of said fusion protein.